

LOTTE BIOLOGICS signs a strategic partnership agreement with Asimov

17 March 2025 | News

Establishing an End-to-End Service partnership, from Cell Line development to GMP manufacturing



LOTTE BIOLOGICS has signed a Memorandum of Understanding (MOU) with Asimov, a company headquartered in Boston, Massachusetts, to collaborate in the Contract Development and Manufacturing Organization (CDMO) business.

Through this agreement, LOTTE BIOLOGICS plans to leverage Asimov's next-generation cell line development platform technology to provide end-to-end services, covering the entire process from cell line development to GMP manufacturing. This collaboration is expected to further strengthen LOTTE BIOLOGICS' CDMO capabilities and track record.

LOTTE BIOLOGICS has successfully validated the scalability and large-scale production capabilities of Asimov's proprietary CHO Edge cell line development platform through pilot testing at its Syracuse Bio Campus. Building on these results, this agreement marks the beginning of full-scale collaboration to provide end-to-end services for customers.

Asimov's CHO Edge system is a synthetic biology-based cell line development platform that accelerates the production of antibodies and protein therapeutics through genetic design and optimization of CHO (Chinese Hamster Ovary) cells. In particular, by incorporating process automation and AI-driven analysis, the platform enables the rapid development of customized cell lines with high productivity and consistency.

The integration of the CHO Edge system with LOTTE BIOLOGICS' GMP manufacturing capabilities enables a seamless transition from cell line development to commercial production. This collaboration serves as a pivotal milestone, driving both the expansion of LOTTE BIOLOGICS' CDMO business and Asimov's operational growth.

This partnership agreement is also expected to maximize the advantages of LOTTE BIOLOGICS' U.S.-based manufacturing facility, which recently garnered significant attention.